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Abstract: Objective: To observe the clinical effect of “Chaihu Shugan Powder Zuojin Pill” in the treatment of
non-erosive gastroesophageal reflux disease. Methods: Sixty patients with non-erosive gastroesophageal reflux disease
were randomly divided into treatment group and control group (30 cases in each group). The patients were treated with
“Zaohu Shugan Powder” and “Zangjin Pills” and omeprazole respectively. For 8 weeks, the clinical efficacy and
changes in clinical symptoms were observed. Results: The total effective rate was 93.3% in the treatment group and
80.0% in the control group. There was significant difference between the two groups before and after treatment (P
<0.05). Conclusion: “Chaihu Shugan Powder Zuojin Pill” can effectively improve the clinical symptoms of non-erosive
gastroesophageal reflux disease.
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Introduction
Gastroesophageal reflux disease (GRD) refers to a disease in which the contents of the stomach are refluxed into the
esophagus, causing discomfort and/or complications. GRD can be divided into non-erosive reflux disease (NERD),
erosive esophagitis and Barrett’s esophagus. In the three types of GRD, NERD accounted for about 70%. In 2007,
Switzerland Vevey International Conference reported that NERD is a subtype of GRD, which is a reflux-related
symptom. In the near future, without receiving acid therapy in the case of routine endoscopy failed to find esophageal
mucosal erosion or interruption of the disease[1]. This study aims to find the effects of “Chaihu Shugan Powder Zuojin
Pill” and omeprazole in the treatment of non-erosive GRD.
1. Clinical data
1.1 General information
All the cases studied in this study were outpatient and inpatient cases in our hospital, and 60 cases were included in the
standard. There were 8 males and 23 females with an average age of 53.23 ± 14.33 years. There were 9 males and 22
females with an average age of 54.90 ± 11.53 years. The sex and age of the two groups were comparable (P> 0.05).
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1.2 Diagnostic criteria
Diagnostic criteria of the non-erosive GRD is based on “Chinese Gastroesophageal Reflux disease consensus”[2].(1)
Typical symptoms include pantothenic acid, heartburn, sternal pain discomfort, and nausea.(2)Electronic gastroscopy:
Patient with esophageal mucosal erosion was not included in the endoscopic examination.Besides, patients with
Barrett’s esophagus, erosive esophagitis and complications, such as esophageal inflammation stenosis, ulcers, and
esophageal cancer were excluded.
1.3 Inclusion criteria
(1) Age 18-65 years of age, gender is not limited; (2) there is a typical reflux symptoms at least for more than 3 months;
(3) reflux disease questionnaire (RDQ) ≥ 12 points; (4) no mucosal damage showed in electronic endoscopy; (5) signed
informed consent.
1.4 Exclusion criteria
(1) Electronic gastroscopy examination showed esophageal mucosal erosion, ulcers, Barrett’s esophagus, stomach,
esophageal or duodenal surgery history, peptic ulcer, upper gastrointestinal malignant lesions, dugouts esophagitis, and
pyloric obstruction ; (2) liver and kidney dysfunction, severe cardiovascular disease; (3) pregnant and lactating women;
(4) non-collaborators (that cannot be diagnosed with endoscopy or cannot be prescribed medication and affect the
efficacy);(5) patients with mental illness and who cannot communicate with the doctor.
2. Treatment and observation methods
2.1 General treatment
Patients were forbidden to eat spicy, greasy and other spicy food. Besides, patients should avoid too full and food
consuming 2 h before going to bed. The bed should be raised to 15–20cm. Patient should quit smoking and alcohol.
Patient should avoid food intake that decrease lower esophageal sphincter (LES), such as chocolate, tea, high-fat foods
and high-acid foods.
2.2 Drug treatment
Treatment group was given “Chaihu Shugan Powder Zuojin Pill”, from bupleurum, Citrus aurantium, dried tangerine
peel, Cyperus rotundus, Chuanxiong, white peony root, berberine, and evodia, 1 dose daily and split to 2 times orally. If
epigastric swelling, add magnolia back; if sternum showed obvious pain, add corydalis tuber and fructus meliae
toosendan; if nausea, add Rhizoma Pinelliae Preparata and Amomum Villosum. The control group received omeprazole
20 mg/tablets, 20 mg, 2 times a day, and half an hour before meals orally. Treatment was given for 8 weeks. An
evaluation was carried out after the end of treatment.
2.3 Observation method
The RDQ score of 40 points includes the sum of the frequency and degree of symptoms. Symptoms include acid reflux,
heartburn, chest pain, and nausea. The four symptoms are recorded according to the severity and frequency. The
frequency of the onset of four major clinical symptoms of patients was recorded as: never been, 1 week <1d, 1 week 1d,
1 week 2–3d, 1 week 4–5 days, and almost every day. The points are calculated statistically as 0, 1, 2, 3, 4, and 5 points.
The degree of symptoms of patients were divided into six grades: no, very mild, mild, moderate, severe and very severe,
as 0, 1, 2, 3, 4 and 5 score, respectively.
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2.4 Statistical methods
SPSS 20.0 statistical software was used for statistical analysis. Group data were compared using t-test. The
measurement data were expressed as mean ± standard deviation ( x ± s). The counting data were compared by using
chi-square test.
3. Observation of efficacy
3.1 Criteria for the determination of efficacy[3]
Recovery: clinical symptoms disappeared or disappeared, the score decreased ≥ 95%;
Markedly: symptoms and signs improved significantly, points decreased by ≥ 70% and <95%;
Effective: symptoms and signs are improved, points reduction ≥ 30% and <70%;
Invalid: symptoms and signs were no significant improvement or increase, points decreased by <30%.
3.2 Results
3.2.1 Comparison of clinical efficacy
The total effective rate of the treatment group was 93.3%. The total effective rate of the control group was 80.0%. The
difference between the two groups was statistically significant (P <0.05). Refer to Table 1.
Table 1 Comparison of clinical efficacy between two groups
Group No. of cases Recover Efficiency Effective Ineffective Total efficiency (%)
Treatment group 30 3 22 3 2 93.3*
Control group 30 1 16 7 6 80.0
Note: * P <0.05 when compared with the control group after treatment.
3.2.2 Comparison of symptom scores
There was no significant difference between the two groups before treatment (P> 0.05). There was significant
difference between the two groups before and after treatment (P < (P <0.05). The difference between the two groups
was statistically significant (P <0.05). Refer to Table 2.
4. Discussion
GRD is not presence in the record of traditional Chinese medicine. The majority of doctors determine the disease
according to the clinical manifestations. The pathogenesis of NERD is related to the positions in the esophagus,
stomach, liver and spleen[4]. As the patient diet section and other direct damage to the spleen and stomach, and affecting
the qi.
4 | Liu Q. Advanced Emergency Medicine
Table 2 Symptoms of two groups before and after treatment ( x ± s).
Note: ■ P <0.05 when compared with the control group before treatment; ○ P <0.05 when compared with the control group after treatment.
The Bupleurum is slightly bitter. The “Ben-Jing” records: “the stomach accumulates gas, food accumulation, cold and
heat, pushing the old away”; “Materia Medica by 100 kinds record” contains: “Bupleurum is drug for the stomach, the
smell is light and fresh, remove stagnation of qi.”
Modern pharmacology study proved that Bupleurum, Cyperus rotundus, Citrus aurantium can promote smooth
muscle contraction, increase the tension of the pyloric sphincter, relaxation Oddi sphincter, promote gastrointestinal
emptying, and thereby relieve esophageal gastric motility disorders. Bupleurum in the total Saponins and Citrus
Aurantium volatile oil can significantly reduce the secretion of gastric juice, reduce the activity of pepsin, and improve
the pH value of gastric juice[5]. Coptis, Evodia and licorice can inhibit gastric acid secretion and reduce the pepsin
activity[6]. Total use of drugs can reduce or even inhibit gastric acid secretion, inhibit pepsin activity, increase
gastrointestinal motility, enhance gastrointestinal emptying, relieve or restore esophageal and gastrointestinal motility
disorders.
In conclusion, “Chaihu Shugan Powder Zuojin Pill” is effective for treatment of non-erosive GRD and it is worthy of
clinical use.
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Group Before Treatment After Treatment
Treatment group 18.90±0.26 4.17±0.18■○
Control group 19.73±0.24 9.03±0.19■
